JP2017527559A - ハンチントンタンパク質のイメージング用プローブ - Google Patents

ハンチントンタンパク質のイメージング用プローブ Download PDF

Info

Publication number
JP2017527559A
JP2017527559A JP2017511927A JP2017511927A JP2017527559A JP 2017527559 A JP2017527559 A JP 2017527559A JP 2017511927 A JP2017511927 A JP 2017511927A JP 2017511927 A JP2017511927 A JP 2017511927A JP 2017527559 A JP2017527559 A JP 2017527559A
Authority
JP
Japan
Prior art keywords
pyridin
imaging agent
dihydro
optionally substituted
isoindol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017511927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527559A5 (enExample
Inventor
ドミンゲス，セリア
ウィチャック，ジョン
バード，ジョナサン
ブラウン，クリストファー，ジョン
クルール，トーマス，マーティン
クラーク−フルー，ダニエル
ヘイズ，サラ
Original Assignee
シーエイチディーアイ ファウンデーション，インコーポレーテッド
シーエイチディーアイ ファウンデーション，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエイチディーアイ ファウンデーション，インコーポレーテッド, シーエイチディーアイ ファウンデーション，インコーポレーテッド filed Critical シーエイチディーアイ ファウンデーション，インコーポレーテッド
Publication of JP2017527559A publication Critical patent/JP2017527559A/ja
Publication of JP2017527559A5 publication Critical patent/JP2017527559A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2017511927A 2014-08-29 2015-08-28 ハンチントンタンパク質のイメージング用プローブ Ceased JP2017527559A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043644P 2014-08-29 2014-08-29
US62/043,644 2014-08-29
PCT/US2015/047396 WO2016033436A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020016705A Division JP6843282B2 (ja) 2014-08-29 2020-02-04 ハンチントンタンパク質のイメージング用プローブ

Publications (2)

Publication Number Publication Date
JP2017527559A true JP2017527559A (ja) 2017-09-21
JP2017527559A5 JP2017527559A5 (enExample) 2018-10-04

Family

ID=55400644

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017511927A Ceased JP2017527559A (ja) 2014-08-29 2015-08-28 ハンチントンタンパク質のイメージング用プローブ
JP2020016705A Active JP6843282B2 (ja) 2014-08-29 2020-02-04 ハンチントンタンパク質のイメージング用プローブ
JP2021026146A Active JP7042940B2 (ja) 2014-08-29 2021-02-22 ハンチントンタンパク質のイメージング用プローブ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020016705A Active JP6843282B2 (ja) 2014-08-29 2020-02-04 ハンチントンタンパク質のイメージング用プローブ
JP2021026146A Active JP7042940B2 (ja) 2014-08-29 2021-02-22 ハンチントンタンパク質のイメージング用プローブ

Country Status (20)

Country Link
US (2) US11071793B2 (enExample)
EP (1) EP3186241B1 (enExample)
JP (3) JP2017527559A (enExample)
KR (1) KR102410760B1 (enExample)
CN (2) CN107074817B (enExample)
AU (1) AU2015308765B2 (enExample)
BR (1) BR112017004136B1 (enExample)
CA (1) CA2959531C (enExample)
DK (1) DK3186241T3 (enExample)
EA (1) EA037275B1 (enExample)
ES (1) ES2841746T3 (enExample)
HR (1) HRP20202032T1 (enExample)
HU (1) HUE052892T2 (enExample)
IL (1) IL250805B (enExample)
MX (2) MX383202B (enExample)
PL (1) PL3186241T3 (enExample)
PT (1) PT3186241T (enExample)
SG (1) SG11201701578YA (enExample)
SI (1) SI3186241T1 (enExample)
WO (1) WO2016033436A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507185A (ja) * 2019-12-18 2023-02-21 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチンチンタンパク質をイメージングするための化合物及びプローブ

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein
US10865201B2 (en) 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
EP3509587B1 (en) 2016-09-12 2023-12-06 Valo Health, Inc. Monocyclic compounds useful as gpr120 modulators
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
BR112022025238A2 (pt) * 2020-06-11 2023-02-14 Chdi Foundation Inc Compostos heterocíclicos e agentes de imageamento para formar imagem da proteína huntingtina
WO2022216947A1 (en) * 2021-04-08 2022-10-13 Chdi Foundation, Inc. Isoindolinone compounds and imaging agents for imaging huntingtin protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076969A1 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726197A (en) * 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
KR101011657B1 (ko) * 2002-03-01 2011-01-28 다케다 야쿠힌 고교 가부시키가이샤 항우울제
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
EP2215074B1 (en) * 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009072581A1 (ja) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. ラクタム化合物又はその塩及びｐｐａｒ活性化剤
WO2010104324A2 (ko) * 2009-03-10 2010-09-16 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를 가지는 할로겐화 이소인돌론 화합물, 및 이의 제조 방법 및 용도
BR112014026283B1 (pt) * 2012-04-25 2022-08-02 Raqualia Pharma Inc Compostos da fórmula (i), (ii), (iii), uso dos mesmos, composição farmacêutica, e processo para a preparação de uma composição farmacêutica
WO2015054317A1 (en) * 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076969A1 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507185A (ja) * 2019-12-18 2023-02-21 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチンチンタンパク質をイメージングするための化合物及びプローブ
JP7720847B2 (ja) 2019-12-18 2025-08-08 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチンチンタンパク質をイメージングするための化合物及びプローブ

Also Published As

Publication number Publication date
US12036291B2 (en) 2024-07-16
KR102410760B1 (ko) 2022-06-20
AU2015308765A1 (en) 2017-03-23
EA037275B1 (ru) 2021-03-03
IL250805A0 (en) 2017-04-30
MX383202B (es) 2025-03-13
US20210379211A1 (en) 2021-12-09
AU2015308765B2 (en) 2020-06-04
CA2959531C (en) 2023-01-10
JP2020079272A (ja) 2020-05-28
MX2017002704A (es) 2017-10-23
WO2016033436A1 (en) 2016-03-03
US20170281804A1 (en) 2017-10-05
CA2959531A1 (en) 2016-03-03
HUE052892T2 (hu) 2021-05-28
MX2021005891A (es) 2021-06-23
US11071793B2 (en) 2021-07-27
PT3186241T (pt) 2021-01-08
ES2841746T3 (es) 2021-07-09
BR112017004136B1 (pt) 2022-05-03
JP7042940B2 (ja) 2022-03-28
CN118005611A (zh) 2024-05-10
EP3186241A1 (en) 2017-07-05
CN107074817B (zh) 2023-12-15
BR112017004136A2 (pt) 2017-12-12
SI3186241T1 (sl) 2021-03-31
JP2021088584A (ja) 2021-06-10
HRP20202032T1 (hr) 2021-02-19
SG11201701578YA (en) 2017-03-30
EP3186241B1 (en) 2020-10-07
PL3186241T3 (pl) 2021-05-17
EA201790432A1 (ru) 2017-09-29
IL250805B (en) 2020-08-31
EP3186241A4 (en) 2018-04-18
CN107074817A (zh) 2017-08-18
KR20170047348A (ko) 2017-05-04
DK3186241T3 (da) 2021-01-11
JP6843282B2 (ja) 2021-03-17

Similar Documents

Publication Publication Date Title
JP7042940B2 (ja) ハンチントンタンパク質のイメージング用プローブ
AU2019283999B2 (en) Probes for imaging huntingtin protein
EA035646B1 (ru) Зонды для визуализации белка хантингтина
EP3190888B1 (en) Probes for imaging huntingtin protein
CA2995847C (en) Probes for imaging huntingtin protein
HK1240582B (en) Probes for imaging huntington protein
HK1240582A1 (en) Probes for imaging huntington protein
HK1241223A1 (en) Probes for imaging huntingtin protein
HK1241223B (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20200630